270 reports of this reaction
1.3% of all FEBUXOSTAT TABLETS 40 MG reports
#19 most reported adverse reaction
ALANINE AMINOTRANSFERASE INCREASED is the #19 most commonly reported adverse reaction for FEBUXOSTAT TABLETS 40 MG, manufactured by Macleods Pharmaceuticals Limited. There are 270 FDA adverse event reports linking FEBUXOSTAT TABLETS 40 MG to ALANINE AMINOTRANSFERASE INCREASED. This represents approximately 1.3% of all 21,060 adverse event reports for this drug.
Patients taking FEBUXOSTAT TABLETS 40 MG who experience alanine aminotransferase increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALANINE AMINOTRANSFERASE INCREASED is a less commonly reported adverse event for FEBUXOSTAT TABLETS 40 MG, but still significant enough to appear in the safety profile.
In addition to alanine aminotransferase increased, the following adverse reactions have been reported for FEBUXOSTAT TABLETS 40 MG:
The following drugs have also been linked to alanine aminotransferase increased in FDA adverse event reports:
ALANINE AMINOTRANSFERASE INCREASED has been reported as an adverse event in 270 FDA reports for FEBUXOSTAT TABLETS 40 MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALANINE AMINOTRANSFERASE INCREASED accounts for approximately 1.3% of all adverse event reports for FEBUXOSTAT TABLETS 40 MG, making it a notable side effect.
If you experience alanine aminotransferase increased while taking FEBUXOSTAT TABLETS 40 MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.